PhD, Epidemiology, Johns Hopkins University
MHS, Biostatistics, Johns Hopkins University
MPH, Tehran University of Medical Sciences
MD, Tehran University of Medical Sciences

Certifications:
CRA, Research Administrators Certification Council 
CPRA, Research Administrators Certification Council 
CFRA, Research Administrators Certification Council 

Certificates:
Organizational Leadership, Harvard Business School
Financial Accounting, Harvard Business School

Dr. Farin Kamangar is a University Distinguished Professor and Associate Vice President for Research at Morgan State University. He is a cancer epidemiologist, and has published over 270 peer-reviewed articles, many in top-tier journals such as The Lancet, BMJ, Annals of Internal Medicine, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute, and Gastroenterology.

Dr. Kamangar has served as the PI or co-PI of over $50 million of NIH-funded projects, including the ASCEND Training Model to the Enhance the Diversity of Biomedical Research Workforce, as well as major epidemiologic studies, including the Golestan Cohort Study, a large cohort study of over 50,000 individuals with over 20 years of follow up. He is a Fellow of the American Association for the Advancement of Science (AAAS) and has received several research awards, including the NIH Merit Award (group award) and the NCI Director's Innovation Award. Dr. Kamangar has collaborated with researchers at NIH, Johns Hopkins, University of Maryland, International Agency for Research on Cancer, and Tehran University of Medical Sciences, among others. 

Dr. Kamangar has a passion for teaching and mentoring. He has taught at all levels, from high school to the doctoral level, and has significant experience in teaching and mentoring minority students.

Research Interests:
Epidemiology of chronic diseases, with an emphasis on epidemiology of esophageal and gastric cancers. Other areas of interest are carcinogenicity of opium, polycyclic aromatic hydrocarbons, and hot beverages, as well as effects of opium use on cardiovascular diseases and other chronic conditions.

Selected Publications (Total > 270, Google Scholar H-Index: 82, Citations > 35,000):
https://scholar.google.com/citations?user=kxKoVTMAAAAJ&hl=en

• Kamangar F, Nesheli DN, Safiri S, Sepanlou SG, Islami F, Malekzadeh R, Naghavi M (on behalf of the Global 2017 Oesophageal Cancer Collaborators). Global, regional, and national burden of oesophageal cancer and its attributable risk factors, 1990 - 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterology and Hepatology 2020, 5: 582-597.
• Rahmati A, Shakeri R, Khademi H, Poustchi H, Pourshams A, Etemadi A, Khoshnia M, Sohrabpour AA, Aliasgari A, Jafari E, Islami F, Semnani S, Gharavi S, Abnet CC, Pharoah P, Brennan P, Boffetta P, Dawsey SM, Malekzadeh R, Kamangar F. Mortality from respiratory diseases associated with opium use – A population-based cohort study. Thorax 2017, 72:1028-1034.
• Kamangar F, Shakeri R, Malekzadeh R, Islami F. Opium use: A risk factor for multiple cancers? Lancet Oncology 2014, 15: e69 - e77.
• Karimi P, Islami F, Anandasbapathy S, Freedman ND, Kamangar F. Gastric Cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiology, Biomakers, and Prevention 2014, 23: 700 - 713.
• Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, Abaie B, Islami F, Nasseri-Moghaddam S, Byrnes G, Abnet CC, Dawsey SM, Ponder BA, Day NE, Pharoah PD, Boffetta P, Brennan P, Kamangar F. Opium use and mortality in the Golestan Cohort Study: A prospective study of 50,000 adults. BMJ 2012, 344: e2502.
• Kamangar F, Schantz MM, Abnet CC, Fagundes RB, Dawsey SM. High levels of carcinogenic polycyclic aromatic hydrocarbons in maté drinks. Cancer Epidemiology, Biomarkers, and Prevention 2008, 17: 1262 - 1268.
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer, incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology 2006, 24: 2137 - 2150.